Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02961569
Other study ID # TBsputum
Secondary ID
Status Completed
Phase N/A
First received October 18, 2016
Last updated April 26, 2017
Start date July 2016
Est. completion date April 2017

Study information

Verified date April 2017
Source Hopital Lariboisière
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Tuberculosis (TB) is a major cause of death among the "communicable" diseases in the world. Pulmonary TB, the main localization, leads to the dissemination of cases. An earlier diagnosis of contagious pulmonary TB is a cornerstone to stop the air transmission. The aim of the study will be to compare two strategies, in patients with a chest-X-ray in favour of contagious pulmonary TB: the classical strategy of sputa collection during three consecutive early mornings, versus the studied strategy of sputa collection at hour h, hour h+1, hour h+2 during the first early morning.


Description:

Tuberculosis (TB) is a major cause of death among the "communicable" diseases in the world. Pulmonary TB, the main localization, leads to the dissemination of cases. An earlier diagnosis of contagious pulmonary TB is a cornerstone to stop the air transmission by starting earlier treatment. The aim of the study will be to compare two strategies, in patients with a chest-X-ray in favour of pulmonary TB: the classical strategy of sputa collection during three consecutive early mornings, versus the studied strategy of sputa collection at hour h, hour h+1, hour h+2 during the first early morning.


Recruitment information / eligibility

Status Completed
Enrollment 34
Est. completion date April 2017
Est. primary completion date April 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- All adult patients suspected of pulmonary TB (symptoms: lost weight, hemoptysis, chronic cough or fever, or a Chest-X-Ray (CXR) evocative of pulmonary TB)

Exclusion Criteria:

- Patients who refused or were unable to give written consent

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
sputum collection for acid fast bacilli
spontaneous or post fiberoptic bronchoscopy sputa

Locations

Country Name City State
France Hôpital Lariboisière Paris Ile-de-France

Sponsors (1)

Lead Sponsor Collaborator
Hopital Lariboisière

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Comparison between the sensitivities of the two strategies for detection of Acid fast bacilli (AFB) on direct stain Ziehl Neelsen one year
See also
  Status Clinical Trial Phase
Completed NCT00933790 - Comparing Daily vs Intermittent Regimen of ATT in HIV With Pulmonary Tuberculosis Phase 3
Completed NCT04645836 - Impact of a Pharmacist-led Patient-centred Care Intervention Along With Text-Message Reminders, on the Management of Newly Diagnosed Tubercular Patients: a Protocol for a Randomized Controlled Trial'. N/A
Recruiting NCT06058299 - Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis Phase 2
Completed NCT03722472 - Phase 1 Clinical Trial of Single-Vial ID93 + GLA-SE in Healthy Adults Phase 1
Completed NCT03678688 - A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis Phase 1/Phase 2
Completed NCT00212550 - Evaluation of the Practice of Three Morning Sputa on Separate Days for Diagnosis of Mtb N/A
Recruiting NCT03025516 - Performance Evaluation of TB Breath- and Cough-testing Platforms N/A
Recruiting NCT05426720 - Risk Factors and Biomarkers for Post-tuberculosis Lung Damage
Recruiting NCT04264221 - Promoting Overall Care and Management Related to Tuberculosis Infection Through Pharmaceutical Care and Text Messaging N/A
Active, not recruiting NCT05221502 - Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB Phase 2